| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Teduglutide |
| Brand | Revestive® |
| Indication | For the treatment of patients aged 1 year and above with short bowel syndrome. Patients should be stable following a period of intestinal adaptation. |
| Assessment Process | |
| Rapid review commissioned | 13/03/2017 |
| Rapid review completed | 12/04/2017 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 12/04/2017 |
| Pre-submission consultation with Applicant | 15/05/2017 |
| Full submission received from Applicant | 31/07/2017 |
| Preliminary review sent to Applicant | 21/11/2017 |
| NCPE assessment re-commenced | 05/12/2017 |
| Factual accuracy sent to Applicant | 06/02/2018 |
| NCPE assessment re-commenced | 21/02/2018 |
| NCPE assessment completed | 16/03/2018 |
| NCPE assessment outcome | Reimbursement Not Recommended. |
The HSE has approved reimbursement following confidential price negotiations January 2021.